Малта - английски - Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - film-coated tablet - sitagliptin 25 mg - drugs used in diabetes

Малта - английски - Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - film-coated tablet - sitagliptin 50 mg - drugs used in diabetes

Малта - английски - Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - film-coated tablet - sitagliptin 100 mg - drugs used in diabetes

Европейски съюз - английски - EMA (European Medicines Agency)

merck sharp and dohme b.v - sitagliptin - diabetes mellitus, type 2 - drugs used in diabetes - for adult patients with type-2 diabetes mellitus, januvia is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a peroxisome-proliferator-activated-receptor-gamma (pparγ) agonist (i.e. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control;a pparγ agonist (i.e. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination with:a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.januvia is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Европейски съюз - английски - EMA (European Medicines Agency)

merck sharp & dohme b.v. - sitagliptin - diabetes mellitus, type 2 - drugs used in diabetes - for adult patients with type-2 diabetes mellitus, ristaben is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a peroxisome proliferator-activated-receptor-gamma (pparγ) agonist (i.e. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination with:a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.ristaben is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Европейски съюз - английски - EMA (European Medicines Agency)

merck sharp & dohme b.v. - sitagliptin - diabetes mellitus, type 2 - drugs used in diabetes - for adult patients with type-2 diabetes mellitus, xelevia is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i.e. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination with:a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.xelevia is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Европейски съюз - английски - EMA (European Medicines Agency)

merck sharp & dohme b.v. - sitagliptin - diabetes mellitus, type 2 - drugs used in diabetes - for patients with type-2 diabetes mellitus, tesavel is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a pparγ agonist (i.e. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination witha sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control;a peroxisome-proliferator-activated-receptor-gamma (pparγ) agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control.tesavel is also indicated as add on to insulin (with or without metformin) when diet and exercise plus stable dosage of insulin do not provide adequate glycaemic control.

Великобритания - английски - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - sitagliptin phosphate - tablet - 100mg

Великобритания - английски - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - sitagliptin phosphate - tablet - 50mg

Великобритания - английски - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - sitagliptin phosphate - tablet - 25mg